The Indian Council of Medical Research (ICMR) and Panacea Biotec Limited announced the initiation of the first ever phase 3 clinical trial for a dengue vaccine in India.
DengiAll
Developed by: Panacea Biotec, commenced with the first participant vaccinated at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak.
Vaccine Background: The tetravalent dengue vaccine strain (TV003/TV005), originally developed by the U.S. National Institutes of Health, has demonstrated promising results in both preclinical and clinical trials globally.
Development Stage: Panacea Biotec, one of three Indian companies to receive the vaccine strain, is at the most advanced stage of developing and testing the vaccine in India.
Course Purchase Query 